knowledge -WSS

knowledge

author：hotspot 2025-09-28 23:48:31 - browse：2148

intarcia implant. -- health tech coverage from STAT — The matchstick-sized, implantable device from Intarcia Therapeutics releases a steady, continuous, and low-dose stream of a drug for diabetes. Stuart Isett/Fortune Brainstorm Health

An advisory panel to the Food and Drug Administration unanimously voted against a diabetes implant from Intarcia Therapeutics — a former biotech unicorn that faltered after the FDA rejected said implant not once, but twice.

Intarcia called for the panel meeting because of those two rejections, seeking outside input on the FDA’s decision. FDA then granted Intarcia’s request. The agency is not bound to advisory panel decisions, though it tends to follow their advice.

Intarcia started developing its lead therapy, a small, skinny bar implanted under the skin, for type 2 diabetes patients in 2016. The implant delivers a glucose-controlling medicine called exenatide, a member of the GLP-1 drugs that have taken the diabetes and obesity markets by storm. Intarcia’s implant continuously administers the drug over six months, with the goal of improving patient adherence compared to Eli Lilly and Novo Nordisk’s weekly GLP-1 shots.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen
Next article： Adam's Take: Intra

WSS

Trump Organization, Michael Cohen agree to settle million

Erich Jarvis studies song birds to learn about human stuttering

Texas board proposes rules on abortion law emergency exemption

Hey, doctors: Don't be no

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Why Marc Tessier

entertainment

knowledge

leisure time

Novavax promises a turnaround & Lilly roils the obesity market

Mega Millions jackpot grows to $720 million ahead of Friday's drawing

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Suspects arrested after 3 women attacked on Manhattan's West Side: Police

Moonlake's readout produced a cash windfall. Risks remain

'The View' co

Supreme Court strikes down use of affirmative action

Yancopoulos of Regeneron works to expand Dupixent success

Activists slam private health insurers over coverage restrictions

Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

focus

A new deal aims to ramp up use of AI in rehab care decisions

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

What is artificial intelligence? Experts weigh in

Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

Family of Gilgo Beach murder suspect releases statement: 'Devastating time'

Chinese researcher claims birth of first gene

focus

focus

explore

knowledge